ZA200106353B - Method for the prevention or reduction of cariovascular events associated with coronary intervention. - Google Patents
Method for the prevention or reduction of cariovascular events associated with coronary intervention. Download PDFInfo
- Publication number
- ZA200106353B ZA200106353B ZA200106353A ZA200106353A ZA200106353B ZA 200106353 B ZA200106353 B ZA 200106353B ZA 200106353 A ZA200106353 A ZA 200106353A ZA 200106353 A ZA200106353 A ZA 200106353A ZA 200106353 B ZA200106353 B ZA 200106353B
- Authority
- ZA
- South Africa
- Prior art keywords
- days
- coronary intervention
- treatment period
- composition according
- dosage
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 51
- 230000002265 prevention Effects 0.000 title claims description 18
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 230000007211 cardiovascular event Effects 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 22
- 208000037803 restenosis Diseases 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 11
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 230000000250 revascularization Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000007887 coronary angioplasty Methods 0.000 claims description 7
- -1 dimethoxycinnamoyl Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- NZHGWWWHIYHZNX-UHFFFAOYSA-N 2-((3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl)amino)benzoic acid Chemical compound C1=C(OC)C(OC)=CC=C1C=CC(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-UHFFFAOYSA-N 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 44
- 229960005342 tranilast Drugs 0.000 description 41
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 26
- 230000003902 lesion Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 8
- 239000003826 tablet Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000010339 dilation Effects 0.000 description 5
- FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 4
- 229940127291 Calcium channel antagonist Drugs 0.000 description 4
- 229940127218 antiplatelet drug Drugs 0.000 description 4
- 239000000480 calcium channel blocker Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000002823 nitrates Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11846299P | 1999-02-03 | 1999-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200106353B true ZA200106353B (en) | 2002-08-02 |
Family
ID=22378750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200106353A ZA200106353B (en) | 1999-02-03 | 2001-08-02 | Method for the prevention or reduction of cariovascular events associated with coronary intervention. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1171116A4 (fr) |
| JP (1) | JP2002536327A (fr) |
| KR (1) | KR20010101934A (fr) |
| CN (1) | CN1345237A (fr) |
| AU (1) | AU2636600A (fr) |
| BR (1) | BR0007921A (fr) |
| CA (1) | CA2361581A1 (fr) |
| CO (1) | CO5150206A1 (fr) |
| HK (1) | HK1045104A1 (fr) |
| HU (1) | HUP0200129A3 (fr) |
| IL (1) | IL144721A0 (fr) |
| MX (1) | MXPA01007835A (fr) |
| NO (1) | NO20013788L (fr) |
| PL (1) | PL351397A1 (fr) |
| TR (1) | TR200102245T2 (fr) |
| WO (1) | WO2000045811A1 (fr) |
| ZA (1) | ZA200106353B (fr) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617407B2 (ja) * | 1992-09-14 | 1997-06-04 | キッセイ薬品工業株式会社 | 血管内膜細胞過剰増殖疾患の予防および治療剤 |
| CA2153553A1 (fr) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Emulsion stable de lipides |
| AU6837096A (en) * | 1995-09-07 | 1997-03-27 | Kissei Pharmaceutical Co. Ltd. | 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells |
| US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
-
2000
- 2000-02-02 BR BR0007921-9A patent/BR0007921A/pt not_active Application Discontinuation
- 2000-02-02 WO PCT/US2000/002622 patent/WO2000045811A1/fr not_active Application Discontinuation
- 2000-02-02 PL PL00351397A patent/PL351397A1/xx not_active Application Discontinuation
- 2000-02-02 HU HU0200129A patent/HUP0200129A3/hu unknown
- 2000-02-02 KR KR1020017009744A patent/KR20010101934A/ko not_active Application Discontinuation
- 2000-02-02 MX MXPA01007835A patent/MXPA01007835A/es unknown
- 2000-02-02 TR TR2001/02245T patent/TR200102245T2/xx unknown
- 2000-02-02 AU AU26366/00A patent/AU2636600A/en not_active Abandoned
- 2000-02-02 CA CA002361581A patent/CA2361581A1/fr not_active Abandoned
- 2000-02-02 IL IL14472100A patent/IL144721A0/xx unknown
- 2000-02-02 JP JP2000596931A patent/JP2002536327A/ja not_active Withdrawn
- 2000-02-02 CN CN00803384A patent/CN1345237A/zh active Pending
- 2000-02-02 EP EP00904640A patent/EP1171116A4/fr not_active Withdrawn
- 2000-02-03 CO CO00006604A patent/CO5150206A1/es unknown
-
2001
- 2001-08-02 ZA ZA200106353A patent/ZA200106353B/en unknown
- 2001-08-02 NO NO20013788A patent/NO20013788L/no not_active Application Discontinuation
-
2002
- 2002-07-12 HK HK02105201.2A patent/HK1045104A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002536327A (ja) | 2002-10-29 |
| IL144721A0 (en) | 2002-06-30 |
| HUP0200129A3 (en) | 2003-06-30 |
| BR0007921A (pt) | 2002-09-10 |
| NO20013788D0 (no) | 2001-08-02 |
| CA2361581A1 (fr) | 2000-08-10 |
| PL351397A1 (en) | 2003-04-07 |
| TR200102245T2 (tr) | 2002-05-21 |
| AU2636600A (en) | 2000-08-25 |
| HUP0200129A2 (hu) | 2002-05-29 |
| WO2000045811A1 (fr) | 2000-08-10 |
| NO20013788L (no) | 2001-09-28 |
| MXPA01007835A (es) | 2002-04-24 |
| HK1045104A1 (zh) | 2002-11-15 |
| CO5150206A1 (es) | 2002-04-29 |
| CN1345237A (zh) | 2002-04-17 |
| EP1171116A4 (fr) | 2004-11-17 |
| EP1171116A1 (fr) | 2002-01-16 |
| KR20010101934A (ko) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5385935A (en) | Method for the inhibition of restenosis associated with coronary intervention | |
| KR100298807B1 (ko) | 파킨슨씨병및파킨슨증후군의치료를위한,리루졸을포함하는제약학적조성물 | |
| WO2005084392A2 (fr) | Formulations a base de 4-methylpyrazole destinees a inhiber l'intolerance a l'ethanol | |
| US20030191137A1 (en) | Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz | |
| ZA200106353B (en) | Method for the prevention or reduction of cariovascular events associated with coronary intervention. | |
| AU2978500A (en) | Method for the prevention or reduction of cardiovascular events associated with coronary intervention | |
| WO2001097798A1 (fr) | Procede servant a prevenir ou a reduire des evenements cardio-vasculaires induits par intervention coronarienne | |
| WO2001062241A1 (fr) | Procede permettant de prevenir ou reduire les dysfonctionnements de l'acces vasculaire | |
| KR100817932B1 (ko) | 베르바민을 유효성분으로 포함하는 혈관 재협착 예방제 | |
| JP2022518678A (ja) | 炎症性腸疾患の処置のための治療用配合物及び組成物 | |
| US20080139668A1 (en) | Pharmaceutical composition for obovatol for the prevention and treatment of restenosis | |
| KR100806541B1 (ko) | 아세클로페낙을 함유하는 제어 방출성 제제 | |
| AU627277B2 (en) | A method of treatment or prevention of post-ptca restenosis by post-ptca restenosis inhibitor | |
| US11154561B2 (en) | Preventative or therapeutic agent for pulmonary hypertension including crude drug component | |
| US20040048807A1 (en) | Angiogenesis inhibitors | |
| US5354770A (en) | Using imidazolyl tetrahydronaphthalene carboxylic acids to inhibit restenosis | |
| KR960008229B1 (ko) | 캡토프릴 서방성 정제 및 그의 제조방법 | |
| WO2002056941A2 (fr) | Methode de traitement de l'acrosyndrome | |
| JPH02289515A (ja) | Ｐｔｃａ後の再狭窄抑制剤 | |
| WO2007014586A1 (fr) | Utilisation de l'acétate de mégestrol dans le traitement de maladies pulmonaires obstructives | |
| MXPA05005078A (en) | Pharmaceutical composition having a higher ciprofloxacin bioavailability |